Alkermes Plc Stock Price, News & Analysis

Alkermes plc (Nasdaq: ALKS) announced the acceptance of two abstracts for the upcoming 2021 ASCO Annual Meeting from June 4-8, 2021, showcasing their investigational therapy, nemvaleukin alfa. The data will detail its efficacy and tolerability from the ARTISTRY-1 and ARTISTRY-2 clinical trials. The first abstract discusses nemvaleukin monotherapy and its combination with KEYTRUDA in advanced solid tumors, while the second focuses on selecting the recommended phase 2 dose for subcutaneous administration. These presentations represent critical steps in the development of new cancer therapies.

Alkermes plc (Nasdaq: ALKS) reported Q1 2021 revenues of $251.4 million, up from $246.2 million year-over-year. Proprietary product sales totaled $130.0 million, with VIVITROL® declining by 5% to $74.5 million and ARISTADA® increasing 9% to $55.4 million. The net GAAP loss was $22.4 million ($0.14 per share), an improvement from last year's loss of $38.7 million. Alkermes reiterated its 2021 financial expectations and highlighted advancements in its drug pipeline, including the anticipated launch of LYBALVI™.

Alkermes has launched Myrelationshipwithalcohol.com, a website aimed at educating the public about alcohol dependence. This chronic disease affects millions, yet awareness of treatment options remains low. The site features educational resources, an interactive questionnaire from the NIH, and personal recovery stories to destigmatize the condition. Alkermes aims to empower individuals and caregivers to seek professional help. As a key player in this space, the company is focused on enhancing understanding and accessibility of treatment for alcohol dependence.

Alkermes plc (Nasdaq: ALKS) has initiated the ARTISTRY-6 phase 2 trial to assess the efficacy and safety of nemvaleukin alfa, its lead immuno-oncology candidate, in patients with melanoma previously treated with anti-PD-(L)1 therapy. The trial focuses on the effects of both intravenous and subcutaneous nemvaleukin in advanced mucosal and cutaneous melanoma, respectively. With approximately 110 patients to be enrolled, the study aims to evaluate primary endpoints related to overall response rates as well as secondary endpoints such as safety, duration of response, and quality of life.

Alkermes plc (Nasdaq: ALKS) announced a conference call and webcast to discuss its first quarter 2021 financial results on April 28, 2021, at 8:00 a.m. ET. The call will provide insights into the company's performance and updates on its operations. Interested parties can access the webcast and slides on Alkermes' website, and a replay will be available until May 5, 2021. Alkermes specializes in developing innovative medicines in neuroscience and oncology, with a focus on conditions such as addiction and schizophrenia.

Alkermes plc (Nasdaq: ALKS) presented new research from its psychiatry portfolio at the 2021 Congress of the Schizophrenia International Research Society, held virtually from April 17-21. Key findings included subgroup analyses from the phase 3 ENLIGHTEN-2 study of LYBALVI, highlighting its effect on weight gain in at-risk patients and cardiometabolic risk factors. Additionally, results from the ALPINE study suggested handwriting kinematics as a potential biomarker for treatment response in schizophrenia. Alkermes aims to advance mental health treatment options through ongoing research.

On April 7, 2021, Alkermes plc (Nasdaq: ALKS) announced a clinical trial collaboration with MSD to conduct a phase 3 study evaluating its investigational immunotherapy nemvaleukin alfa in combination with KEYTRUDA for platinum-resistant ovarian cancer. Alkermes will lead the study, expected to start in late 2021. The collaboration aims to address a significant treatment gap, as current options for these patients are limited. Early studies indicate promising antitumor activity of the combination, suggesting potential for improved outcomes in this challenging cancer type.

Alkermes plc (Nasdaq: ALKS) will participate in a virtual fireside chat at Stifel's 3rd Annual CNS Day on April 1, 2021, at 8:30 a.m. ET. The event will be accessible on the company's website and archived for 14 days. Alkermes is a biopharmaceutical company developing medicines for neuroscience and oncology, with a portfolio focused on addiction and schizophrenia. Their pipeline includes candidates for schizophrenia, bipolar I disorder, neurodegenerative disorders, and cancer.

On March 25, 2021, Alkermes plc (Nasdaq: ALKS) hosted a virtual Investor Day to discuss its research and development strategy, including updates on the nemvaleukin alfa clinical program and new preclinical initiatives in neuroscience and immuno-oncology.

CEO Richard Pops highlighted the company's reimagined R&D approach, aiming for innovative medicines that address unmet patient needs. The event included presentations on innovative molecular design and ongoing clinical research, promoting the company's commitment to scientific excellence and shareholder value creation.